Rejuvesol
rejuvesol red blood cell processing solution
Approved
Approval ID
bc06c40f-81a0-45e5-80b6-61f67d445068
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Feb 14, 2023
Manufacturers
FDA
Citra Labs, LLC
DUNS: 962863838
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Sodium Pyruvate, Inosine, Adenine, Sodium Phosphate, Dibasic, and Sodium Phosphate, Monobasic, Monohydrate
PRODUCT DETAILS
NDC Product Code23731-7000
Application NumberBN950522
Marketing CategoryC73594
Route of AdministrationEXTRACORPOREAL
Effective DateFebruary 14, 2023
Generic NameSodium Pyruvate, Inosine, Adenine, Sodium Phosphate, Dibasic, and Sodium Phosphate, Monobasic, Monohydrate
INGREDIENTS (5)
SODIUM PYRUVATEActive
Quantity: 0.55 g in 50 mL
Code: POD38AIF08
Classification: ACTIB
SODIUM PHOSPHATE, DIBASICActive
Quantity: 0.73 g in 50 mL
Code: GR686LBA74
Classification: ACTIB
INOSINEActive
Quantity: 1.34 g in 50 mL
Code: 5A614L51CT
Classification: ACTIB
ADENINEActive
Quantity: 0.034 g in 50 mL
Code: JAC85A2161
Classification: ACTIB
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEActive
Quantity: 0.311 g in 50 mL
Code: 593YOG76RN
Classification: ACTIB